According to a modern multicenter ...
According to a modern multicenter study published in the May issue of in every one's mouth Medical Research and Opinion, more than half of the trial's Alzheimer's disease make subordinates who had previously failed to be agreeable to to, or could not tolerate treatment with donepezil (Pfizer Corporation, recently made known York, NY, Aricepo showed significant benefits when treated with Exelon (Novartis Pharmaceuticals Corporation, East Hanover, NJ rivastigmine). The open-label, prospective, six-month application of mind involved 382 subjects at 91
|